ABL
Morgane Bolle is an experienced professional in the bioproduction and quality control sectors, currently serving as Team Leader in production at Oxford Biomedica since April 2021. Prior to this role, Morgane has worked as a bioproduction technician at ABL Europe since February 2016 and gained experience as a quality control laboratory technician at Eli Lilly and Company from 2013 to 2014. Morgane's early career includes an internship at the Centre d'analyse et de recherche in 2013. Academic credentials include a professional license in chemical and pharmaceutical industry with a focus on quality control from IUT Robert Schuman (2013-2014), a DUT in chemistry from the same institution (2011-2013), and a BAC in laboratory sciences from Lycée Varoquaux (2007-2011).
ABL
From development to market ABL Europe provides GMP viral vectors, contributing to the success of our clients’ immunotherapy innovations. ABL Europe SAS is a pure-play GMP CMO licensed in accordance with EMA, completely dedicated to the provision of viral vector GMP contract manufacturing services, and a subsidiary of ABL Inc. under the corporate ownership of Institut Mérieux. ABL has a strong technical & regulatory track record in process development, scale-up & GMP manufacturing of filterable & non-sterile filterable (aseptic processing) viral vectors used in all phases of clinical development globally. With different adherent platforms (< 60 m2) and suspension (< 500 L) capabilities for drug substance and drug product (< 10,000 vials per batch) in-house, experience in process characterisation and validation, ABL provides its clients with a long-term strategic manufacturing option through clinical development & licensure for a range of virus vector gene therapy & vaccine products. ABL Europe’s clients are located worldwide.